Diagnosis of Sickle Cell Anemia

The Sickle Cell Association of Ontario (SCAO) is a non-profit charitable organization, established in 1981 after it became evident that there was a need to educate the public about sickle cell anemia. Also, to provide moral support to parents and families of children, spouses, other relatives and individuals who suffer from sickle cell anemia.

However the area she is from has a high incidence of sickle cell anemia in the population.

Every effort is made to keep the website up and running smoothly. However, American Sickle Cell Anemia Association takes no responsibility for, and will not be liable for, the website being temporarily unavailable due to technical issues beyond our control.


Mayo, T. (2011). Sickle cell anemia. Retrieved from

1. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia, a molecular disease.  ;110:-

In the process of performing a diagnosis to a person suffering from sickle cells anemia or being a carrier of the disorder, a blood test may be carried out to help in checking defective hemoglobin. This process is achieved through the use of a certain tool termed as the hemoglobin electrophoresis. The test is fit for both children and adults considered that the problem affects both populaces. Current research explains that most countries have implemented a law that every newborn child has to go through a sickle cell anemia test before leaving the hospital. In addition, expectant mothers may also decide to have unborn children tested for the same prior to the delivery period.


Thesis on sickle cell anemia. Coursework Service

Sickle cell disease (SCD) is an autosomal recessive disease in which homozygosity for a single point mutation in the gene encoding the β-globin chain produces hemoglobin S molecules that polymerize within the erythrocyte during deoxygenation; the result is sustained hemolytic anemia and vaso-occlusive events. As patients live to adulthood, the chronic impact of sustained hemolytic anemia and episodic vaso-occlusive episodes leads to progressive end-organ complications. This scenario culminates in the development of 1 or more major cardiovascular complications of SCD for which there are no approved or consensus therapies. These complications include elevated pulmonary artery systolic pressure, pulmonary hypertension, left ventricular diastolic heart disease, dysrhythmia, sudden death, and chronic kidney disease with associated proteinuria, microalbuminuria, and hemoglobinuria. In patients with advancing age, cardiopulmonary organ dysfunction and chronic kidney injury have significant effects on morbidity and premature mortality. Over the last 15 years, a number of tests have been validated in multiple replicate cohort studies that identify patients with SCD at the highest risk of experiencing pulmonary and systemic vasculopathy and death, providing for screening strategies tied to targeted, more aggressive diagnostic and therapeutic interventions.

Sickle Cell Research Paper patients with sickle cell disease

Individuals suffering from sickle cell anemia are most likely to experience high blood pressure in the lungs and breathing difficulties hence leading to pulmonary hypertension. Sickle cells may also lead to the damaging of body organs such as the spleen, kidney, and liver due to blockages of blood flow in body vessels hence reducing the amount of blood and oxygen in an organ or tissue. The affected may also loose eyesight and skin ulcers; the latter may lead to the advancement of open sores especially on the legs. Additionally, one may experience gallstones and priapism leading to the blockage of male organs.